Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
Ellie Hershberger, Susan Sloan, Kristin Narayan, Catherine A Hay, Patrick Smith, Frank Engler, Rienk Jeeninga, Saskia Smits, Jose Trevejo, Zach Shriver, David Oldach, Ellie Hershberger, Susan Sloan, Kristin Narayan, Catherine A Hay, Patrick Smith, Frank Engler, Rienk Jeeninga, Saskia Smits, Jose Trevejo, Zach Shriver, David Oldach
Abstract
Background: VIS410, a broadly neutralizing monoclonal antibody that binds the hemagglutinin stem of influenza A viruses, was safe and efficacious in a human H1N1 virus challenge study. This study evaluated the safety and tolerability of VIS410 in non-hospitalized adult patients with uncomplicated influenza A.
Methods: Patients 18 to 65 years of age with symptom onset within 72 h were randomized 1:1:1 to receive a single intravenous infusion of VIS410 4000 mg, 2000 mg, or placebo. Neuraminidase inhibitor therapy was prohibited. Treatment-emergent adverse events (TEAEs) were evaluated up to 100 days post-infusion. Influenza symptoms were assessed daily for 10 days using the FLU-PRO tool. Nasopharyngeal virus shedding was assessed by quantitative reverse-transcription PCR (qRT-PCR) and viral culture through Day 7.
Findings: Of the 150 patients randomized, 148 received study drug, and 138 were confirmed influenza A positive. Median age was 42 years; median time from symptom onset to treatment was 42 h; 93% had influenza A subtype H3N2.
Safety: TEAEs, most commonly diarrhea of mild severity, were dose-related, occurring in 55%, 35%, and 24% of the 4000 mg, 2000 mg, and placebo patients, respectively. Two serious adverse events occurred, both in placebo patients.
Symptom analyses: Baseline FLU-PRO symptom scores were balanced among groups. Mean scores were lower by Days 3 and 4 in the pooled VIS410 treatment group versus placebo (p < 0.023), with a tendency toward faster resolution by Kaplan-Meier analysis.
Virology analyses: VIS410 was associated with reduced median nasopharyngeal viral load TCID50 AUCDay7 (days × log10 TCID50/mL) (3.66 pooled VIS410 vs 4.78 placebo, p = 0.08) and in the subset of patients with baseline hemagglutination inhibition (HAI) titer ≤40 (overall, 74% of patients) was significantly reduced vs placebo (4.218 pooled VIS410 vs 6.152 placebo, p = 0.009). Kaplan-Meier estimated time to resolution of viral shedding was reduced (1.9 vs 3.6 days, p = 0.03) in VIS410 treated patients. There was a trend toward greater proportion of culture-negative patients by Day 3 (66.7% vs 51.1%, p = 0.11); when this analysis was limited to the subset of patients with positive baseline cultures, this difference became more pronounced (63.2% vs 42.5%, p = 0.053). No differences were observed in nasopharyngeal influenza qRT-PCR profiles, which represent both live and neutralized virus.
Interpretation: VIS410 was safe and well tolerated in adults with uncomplicated influenza A, with favorable effects on symptom resolution and virus replication.
Trial registration: Clinical Trials: NCT02989194.
Funding: This project was funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201500018C.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Figures
References
- WHO . Feb. 2010. Guidelines for pharmacological management of Pandemic influenza A(H1N1) 2009 and other influenza viruses. Revised.
- Hayden F.G., Sugaya N., Hirotsu N. Baloxavir Marboxil for Uncomplicated Influenza in adults and Adolescents. N Engl J Med. 2018;379(10):913–923.
- Reed C., Chaves S.S., Daily Kirley P. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3)
- Luke T.C., Kilbane E.M., Jackson J.L., Hoffman S.L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609.
- Hung I.F., To KK, Lee C.K. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza a (H1N1) 2009 virus infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(4):447–456.
- Hung I.F.N., To KKW, Lee C.K. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464–473.
- Beigel J.H., Tebas P., Elie-Turenne M.C. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 2017;5(6):500–511.
- Wollacott A.M., Boni M.F., Szretter K.J. Safety and Upper respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 support Treatment and Prophylaxis based on Population Modeling of Seasonal Influenza a Outbreaks. EBioMedicine. 2016;5:147–155.
- Trevejo J.M., SEKS Sloan, Bedard S., Hay C.A. International Conference of Respiratory and Critical Care Medicine. American Thoracic Society; San Francisco, CA: 2016. Safety and efficacy of the monoclonal antibody VIS410 in a human volunteer challenge model of infection with an H1N1 Influenza A virus.
- Powers J.H., 3rd, Bacci E.D., Guerrero M.L. Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO(c)) scores in Influenza-positive patients. Value Health J Int Soc Pharmacoeconomics Outcome Res. 2018;21(2):210–218.
- Powers J.H., Guerrero M.L., Leidy N.K. Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis. 2016;16:1.
- Garten R., Blanton L., Elal A.I.A. Update: Influenza activity in the United States during the 2017-18 season and Composition of the 2018-19 Influenza Vaccine. MMWR Morb Mortal Wkly Rep. 2018;67(22):634–642.
- Hammond A., Laurenson-Schafer H., Marsland M. World Health Organization Weekly Epidemiological Record. Vol. 93. 2018. Review of the 2017-2018 influenza season in the Northern Hemisphere; pp. 429–444.
- The Lancet Infectious D How to be ready for the next influenza pandemic. Lancet Infect Dis. 2018;18(7):697.
- The Lancet Infectious D Plotting a route to a universal influenza vaccine. Lancet Infect Dis. 2018;18(5):475.
- Popova L., Smith K., West A.H. Immunodominance of antigenic site B over site a of hemagglutinin of recent H3N2 influenza viruses. PLoS One. 2012;7(7)
- Shah D.K., Betts A.M. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5(2):297–305.
- Abbo L., Quartin A., Morris M.I. Pulmonary imaging of pandemic influenza H1N1 infection: relationship between clinical presentation and disease burden on chest radiography and CT. Br J Radiol. 2010;83(992):645–651.
- Taubenberger J.K., Morens D.M. The pathology of influenza virus infections. Annu Rev Pathol. 2008;3:499–522.
- Erbelding E.J., Post D.J., Stemmy E.J. A Universal Influenza Vaccine: the Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis. 2018;218(3):347–354.
- Coughlan L., Palese P. Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine. Cell Host Microbe. 2018;24(1):18–24.
- Nachbagauer R., Palese P. Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. Curr Opin Immunol. 2018;53:51–57.
- Andrews S.F., Graham B.S., Mascola J.R., AB McDermott. Is it possible to develop a "Universal" Influenza virus vaccine? immunogenetic considerations underlying B-cell biology in the development of a pan-subtype influenza a vaccine targeting the Hemagglutinin stem. Cold Spring Harb Perspect Biol. 2018:10(7).
- Crowe J.E., Jr. Is it possible to develop a "Universal" Influenza virus vaccine? potential for a universal influenza vaccine. Cold Spring Harb Perspect Biol. 2018:10(7).
- Joyce M.G., Wheatley A.K., Thomas P.V. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza a Viruses. Cell. 2016;166(3):609–623.
- Baranovich T., Jones J.C., Russier M. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute respiratory Distress Syndrome. Antimicrob Agents Chemother. 2016;60(4):2118–2131.
- Khurana S., Loving C.L., Manischewitz J. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013;5(200)
- Caskey M., Schoofs T., Gruell H. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185–191.
- Group PIW, Multi-National PIIST, Davey R.T., Jr. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375(15):1448–1456.
- Ali S.O., Takas T., Nyborg A. Evaluation of MEDI8852, an anti-influenza a monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob Agents Chemother. 2018 Oct 24;62(11) (Print 2018 Nov, pii: e00694-18)
- Kallewaard N.L., Corti D., Collins P.J. Structure and function analysis of an antibody recognizing all influenza a subtypes. Cell. 2016;166(3):596–608.
- McBride J.M., Lim J.J., Burgess T. Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human Influenza A virus challenge model. Antimicrob Agents Chemother. 2017:61(11).
- Lim J.L., Nilsson A.C., Silverman M., Mironova N., Kulkarni P., McBride J.M. 28th ECCMID; 2018. The CRANE study: A phase 2b randomized, double-blind, placebo-controlled trial of monoclonal antibody MHAA4549A combined with oseltamivir versus oseltamivir alone for treatment of severe influenza A infection; p. 2018.
- Van Baalen C.A., Els C., Sprong L., van Beek R., van der Vries E., Osterhaus A.D. Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture. J Clin Microbiol. 2014 May;52(5):1672–1677. Epub 2014 Mar 12.
Source: PubMed